Insider Selling: GeneDx (NASDAQ:WGS) CEO Sells 10,501 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $638,145.77. Following the transaction, the chief executive officer owned 104,372 shares in the company, valued at $6,342,686.44. This trade represents a 9.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, June 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $53.77, for a total transaction of $195,669.03.
• On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total transaction of $141,592.68.
• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The stock was sold at an average price of $63.17, for a total transaction of $2,964,757.61.

GeneDx Stock Performance

Shares of GeneDx stock traded up $2.59 during trading hours on Thursday, reaching $59.01. The company’s stock had a trading volume of 658,542 shares, compared to its average volume of 1,045,581. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The company’s 50 day simple moving average is $54.54 and its 200 day simple moving average is $87.44. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The stock has a market cap of $1.75 billion, a P/E ratio of -22.02 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period in the prior year, the company earned ($0.23) EPS. As a group, analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. BTIG Research cut their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Guggenheim reduced their price target on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Several law firms, including Rosen, Pomerantz, Bronstein Gewirtz & Grossman, Kahn Swick & Foti, Levi & Korsinsky, and Bernstein Liebhard, issued fresh reminders about the pending securities class action and the August 3 lead plaintiff deadline for GeneDx investors.
• Neutral Sentiment: The lawsuits focus on claims that investors were harmed during the April 16, 2025 to May 4, 2026 period, with allegations linked to acquisition performance and reimbursement weakness.
• Negative Sentiment: Hagens Berman highlighted that the lawsuit stems from GeneDx’s sharp post-earnings decline and a reported 94% write-off related to the Fabric Genomics acquisition, reinforcing concerns about prior results and execution. Article Title

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC bought a new stake in GeneDx during the 3rd quarter valued at $48,157,000. Sumitomo Mitsui Trust Group Inc. boosted its position in GeneDx by 30.6% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 381,725 shares of the company’s stock worth $49,647,000 after acquiring an additional 89,470 shares during the period. Telemark Asset Management LLC bought a new position in shares of GeneDx in the third quarter worth $12,929,000. SG Americas Securities LLC grew its stake in shares of GeneDx by 937.3% in the fourth quarter. SG Americas Securities LLC now owns 63,181 shares of the company’s stock worth $8,217,000 after purchasing an additional 57,090 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of GeneDx by 1,358.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 205,895 shares of the company’s stock valued at $26,779,000 after purchasing an additional 191,780 shares during the period. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.